ABUS
$4.36
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...
Recent News
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook
Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle technology used in its Covid 19 vaccines. The agreement includes a substantial upfront payment, a non exclusive license, and removes the prospect of future royalties for infectious disease applications. At the same time, Moderna received a positive opinion from the European Medicines Agency for its influenza Covid 19 combination vaccine, mCombriax. These decisions...
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today’s Market Action. Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after resolving a four-year legal dispute with two biopharmaceutical companies in relation to an alleged patent infringement of their lipid nanoparticle (LNP) delivery technology. In a […]
Does $2.25 Billion LNP Settlement And Global License Reshape The Bull Case For Moderna (MRNA)?
In early March 2026, Genevant Sciences and Arbutus Biopharma said they had reached a US$2.25 billion global settlement with Moderna over its past unauthorized use of their lipid nanoparticle delivery technology in COVID-19 vaccines, with Moderna paying US$950 million upfront in July 2026 and up to US$1.30 billion more depending on the outcome of a Section 1498 appeal. The agreement clears all related U.S. and international patent disputes, grants Moderna a global non‑exclusive license for...
Why Moderna (MRNA) Stock Is Trading Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 17.4% in the afternoon session after the company settled a long-running patent dispute over the technology used in its COVID-19 vaccine.
These Stocks Are Today’s Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More
Moderna shares jump after the vaccine maker says it has settled patent litigation tied to its Covid-19 shot.